Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

News SummaryMost relevantAll newsSector news 

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
05/03/2012 | 08:11pm CET

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.

The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012

This information is provided by RNS
The company news service from the London Stock Exchange
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
06:01a GLAXOSMITHKLINE : *rpt/ubs cuts glaxosmithkline price target to 1600 pence - 'ne..
12/06 GLAXOSMITHKLINE : *ubs cuts glaxosmithkline price target to 1600 pence - 'neutra..
12/06 ADAPTIMMUNE THERAPEUTICS : Announces Initiation of Myxoid/Round Cell Liposarcoma..
12/05 GLAXOSMITHKLINE : Dominique Limet to step down as CEO of ViiV Healthcare; Debora..
12/05 Astex Joins the Dementia Discovery Fund as a Strategic Investor
12/05 INNOVIVA : Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients..
12/05 GLAXOSMITHKLINE : Dominique Limet to step down as CEO of ViiV Healthcare; Debora..
12/05 GlaxoSmithKline Says Limet To Step Down As CEO Of ViiV Venture
12/02 INNOVIVA : GSK files EU regulatory submission for once-daily closed triple combi..
12/02 GLAXOSMITHKLINE : NICE recommends first-of-its kind asthma treatment mepolizumab
More news
Sector news : Pharmaceuticals - NEC
04:49p Pharma, biotech stocks fall after Trump comment on drug prices
04:32p MYLAN : EpiPen maker Mylan to restructure and cut its workforce
04:19pDJMARKET SNAPSHOT : Dow, S&P 500 On Track For Records, But Health-care Slumps On T..
02:21pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug -- 2nd Updat..
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/05 Spark Strengthens Case For Hemophilia Gene Therapy
12/05 GLAXOSMITHKLINE : Robust Pipeline Supports Its 5.5% Dividend Yield
12/02 ALZHEIMER'S DISEASE : Does THC Hold The Key To A Cure?
12/02 5%+ DIVIDEND YIELD PORTFOLIO : Trump And The No Good, Very Bad Month (Nov 2016 R..
12/02 Glaxo files marketing application in Europe for inhaled triple combo COPD the..
Financials ( GBP)
Sales 2016 27 380 M
EBIT 2016 7 207 M
Net income 2016 2 570 M
Debt 2016 13 769 M
Yield 2016 5,55%
P/E ratio 2016 31,02
P/E ratio 2017 17,84
EV / Sales 2016 3,10x
EV / Sales 2017 2,88x
Capitalization 71 193 M
More Financials
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,9  GBP
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results